Adimmune Corp. engages in the manufacturing and sales of influenza vaccine. Its products include Trivalent Influenza vaccine, Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin. Its business scope includes research and development, processing, manufacturing, and trading of serum, vaccines, test reagents, biological agents and their bacterial liquids, and raw materials. The company was founded on December 22, 1965 and is headquartered in Taichung, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company